Skip to search boxSkip to navigationSkip to main content

Oral therapy of common superficial fungal infections of the skin

  • Jr Lesher
  • Augusta University
Scholary Output:
Contribution to journal
Article
Peer-review

Open access

Abstract

Although superficial fungal infections of the skin often respond to topical agents, systemic therapy is sometimes necessary. This article gives a review of the effectiveness of the oral antifungal agents fluconazole, itraconazole, and terbinafine in the treatment of pityriasis versicolor, tinea corporis/cruris, and tinea pedis. Four hundred milligrams fluconazole as a single dose and 200 mg itraconazole daily for 5 to 7 days were effective in the treatment of pityriasis versicolor; terbinafine taken orally appears to be ineffective in pityriasis versicolor. Tinea corporis and tinea cruris were effectively treated by 50 to 100 mg fluconazole daily or 150 mg once weekly for 2 to 3 weeks, by 100 mg itraconazole daily for 2 weeks or 200 mg daily for 7 days, and by 250 mg terbinafine daily for 1 to 2 weeks. Tinea pedis has been effectively treated with pulse doses of 150 mg fluconazole once weekly, with 100 mg itraconazole daily for 2 weeks or 400 mg daily for 1 week, and with 250 mg terbinafine daily for 2 weeks.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages S31-S34

Journal (Volume, Issue Number)

Journal of the American Academy of Dermatology (Volume 40, Issue 6 II)

Publication milestones

  • Published - 1999

Publication status

Published - 1999

ISSN

0190-9622

Publication IDs

  • Scopus: 0033062969
  • PubMed: 10367914

Publication metrics

Metrics

SciVal
FWCI
5.34
SciVal
Author count
1
SciVal
citations
48
SciVal
Paper percentile
85
Scopus
citations
Fractional count
1
Fractional count
1
Fractional count
1
Fractional count
1

PlumX, opens in new tab

Citation count
59
Captures
35

Funding Details

This work was supported by a research grant from Pfizer Inc. The author has also received research grants from Janssen, Novartis, and Penederm.